Great. Thanks, everyone, for joining. My name is Scott Schoenhaus. I am the health care tech equity analyst here at KeyBanc. We're a pleasure to have Ben Taylor, CFO of Recursion for a fireside chat.

A decision tree regression system incorporates a set of if-then rules to predict a single numeric value. Decision tree regression is rarely used by itself because it overfits the training data, and so ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the overlooked penny stocks to invest in. On January 12, Alec Stranahan, an analyst at Bank of America Securities, maintained a Hold rating on ...

Abstract: Internet-connected devices generate service function chain (SFC) requests for reliability-sensitive applications such as smart factories and intelligent healthcare. To facilitate reliable ...

LOS ANGELES--(BUSINESS WIRE)--Today, Sweetgreen and Function, in collaboration with Function’s co-founder and Chief Medical Officer Mark Hyman, MD, announced a menu that aims to be first-of-its-kind, ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Diebold Nixdorf isn't as well-known as BigBear.ai, but it could have better growth prospects. Recursion Pharmaceuticals' AI drug discovery gives it a shot at growing larger than BigBear.ai. Will ...

Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to beat earnings when it reports second-quarter 2025 results on Aug. 5 ...